• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed

    3/11/21 4:21:54 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care
    Get the next $ATEC alert in real time by email
    SC 13D 1 d48836dsc13d.htm SC 13D SC 13D

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D

    [Rule 13d-101]

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 204.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

     

     

    Alphatec Holdings, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    02081G201

    (CUSIP Number)

    Cathy A. Birkeland, Esq.

    Alexa M. Berlin, Esq.

    Latham & Watkins LLP

    330 N. Wabash Avenue, Suite 2800

    Chicago, Illinois 60611

    (312) 876-7700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 16, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

     

    (Continued on following pages)

    (Page 1 of 15 Pages)

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. 02081G201    13D    Page 2 of 15 Pages

     

      1.    

      Names of Reporting Persons

     

      Squadron Capital LLC

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      11,395,045

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      11,395,045

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,395,045

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      12.0%1

    14.  

      Type of Reporting Person

     

      OO

     

    1 

    Based on 95,149,633 shares of common stock, par value $0.0001 per share, of the Issuer (“Common Stock”) outstanding as of March 1, 2021, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.


    CUSIP No. 02081G201    13D    Page 3 of 15 Pages

     

      1.    

      Names of Reporting Persons

     

      Squadron Capital Holdings LLC

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      11,395,045

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      11,395,045

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,395,045

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      12.0%1

    14.  

      Type of Reporting Person

     

      OO

     

    1 

    Based on 95,149,633 shares of Common Stock outstanding as of March 1, 2021, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.


    CUSIP No. 02081G201    13D    Page 4 of 15 Pages

     

      1.    

      Names of Reporting Persons

     

      Jennifer N. Pritzker

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      32,200

         8.   

      Shared Voting Power

     

      14,127,850

         9.   

      Sole Dispositive Power

     

      32,200

       10.   

      Shared Dispositive Power

     

      14,127,850

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      14,160,050

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      14.9%1

    14.  

      Type of Reporting Person

     

      IN

     

    1

    Based on 95,149,633 shares of Common Stock outstanding as of March 1, 2021, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.


    CUSIP No. 02081G201    13D    Page 5 of 15 Pages

     

      1.    

      Names of Reporting Persons

     

      David R. Pelizzon

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7.     

      Sole Voting Power

     

      148,837

         8.   

      Shared Voting Power

     

      11,395,045

         9.   

      Sole Dispositive Power

     

      148,837

       10.   

      Shared Dispositive Power

     

      11,395,045

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,543,882

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      12.1%1

    14.  

      Type of Reporting Person

     

      CO

     

    1

    Based on 95,149,633 shares of Common Stock outstanding as of March 1, 2021, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.


    CUSIP No. 02081G201    13D    Page 6 of 15 Pages

     

    Item 1. Security and Issuer.

    This statement relates to the shares of common stock, $0.0001 par value per share (“Common Stock”), of Alphatec Holdings, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 5818 E. Camino Real, Carlsbad, California 92008.

    Item 2. Identity and Background.

    (a)-(c), (f) This Schedule 13D is filed jointly on behalf of Squadron Capital LLC, a Delaware limited liability company (“SC LLC”), Squadron Capital Holdings LLC, a Delaware limited liability company (“SCH LLC”), Jennifer N. Pritzker, a U.S. citizen and David R. Pelizzon, a U.S. citizen. The address of the principal business and principal office of SC LLC is 18 Hartford Rd., Granby, CT 06035. The address of the principal business and principal office of each of SCH LLC and Ms. Pritzker is 104 S. Michigan Ave., Chicago, IL 60603. The address of the principal business and principal office of Mr. Pelizzon is 18 Hartford Rd., Granby, CT 06035.

    The principal business of SC LLC is an investment firm that primarily manages direct investments in operating companies, private equity funds and special situations. SCH LLC is a holding company. The principal business of Ms. Pritzker is President and Chief Executive Officer of Tawani Enterprises, Founder and Chair of the Pritzker Military Museum and Library, Founder of the Pritzker Military Foundation, and Founder of the Tawani Foundation. The principal business of Mr. Pelizzon is President and member of the Managing Committee of SC LLC.

    The name, business address, present principal occupation or employment and citizenship of each member of the managing committee and each executive officer of SC LLC and of each member of the managing committee of SCH LLC is set forth on Schedule A hereto and incorporated herein by reference. SCH LLC does not have any officers.

    The Reporting Persons have entered into a joint filing agreement, dated as of March 11, 2021, a copy of which is attached as Exhibit 1 to this Schedule 13D.

    (d)-(e) During the last five years, neither the Reporting Persons nor any of the individuals referred to in Schedule A hereto have (a) been convicted of a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.


    CUSIP No. 02081G201    13D    Page 7 of 15 Pages

     

    Item 3. Source and Amount of Funds or Other Consideration.

    Effective November 2, 2020, Harry B. Rosenberg and Charles E. Dobrusin resigned as members of the management committee of SC LLC, leaving Ms. Pritzker and Mr. Pelizzon as the sole members of the management committee. No consideration was paid in connection with the resignation.

    On December 16, 2020, SC LLC and certain other purchasers thereto entered into a Purchase Agreement (the “Purchase Agreement”) with the Issuer, pursuant to which SC LLC, among other things, agreed to acquire 8,100,810 shares of Common Stock from the Issuer for a purchase price in cash equal to $11.11 per share, or $89,999,999.10 in the aggregate, in a private placement (the “Private Placement”), which was consummated on March 1, 2021. The purchase price was paid using cash on hand from the trusts that own SCH LLC, the controlling member of SC LLC.

    The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which is filed herewith as Exhibit 2, incorporated herein by reference.

    On December 16, 2020, SC LLC entered into a Debt Exchange Agreement (the “Debt Exchange Agreement”) with the Issuer, pursuant to which SC LLC and Squadron Medical Finance Solutions LLC, a Delaware limited liability company of which SC LLC is the sole member (“Squadron Medical”), agreed to exchange $30,000,000 of the Issuer’s outstanding debt obligations pursuant to the Credit Security and Guaranty Agreement, dated as of November 6, 2018 (as amended, the “Credit Agreement”), by and among the Issuer and its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., and Squadron Medical for the issuance of 2,700,270 shares of Common Stock to SC LLC and Tawani Holdings LLC, an Illinois limited liability company (“Tawani”), based on a price of $11.11 per share (the “Debt Exchange”), pursuant to an exemption under the Securities Act of 1933, as amended (the “Securities Act”) (the “Debt Exchange”). The Debt Exchange was consummated on December 16, 2021.

    The foregoing description of the Debt Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement, which is filed herewith as Exhibit 3, incorporated herein by reference.

    On March 8, 2021, Mr. Pelizzon purchased in the open market 4,003 shares of Common Stock for $15.50 per share and 695 shares of Common Stock for $15.93, for an aggregate purchase price of $73,117.85. The purchase price was paid using cash on hand.

    On March 10, 2021, Ms. Pritzker purchased in the open market 1,000 shares of Common Stock for $16.395 per share, 1,000 shares of Common Stock for $16.4199 per share, and 1,000 shares of Common Stock for $16.31 per share, for an aggregate purchase price of $49,124.90. The purchase price was paid using cash on hand.

    Item 4. Purpose of Transaction.

    The securities beneficially owned by the Reporting Persons are held for investment purposes. See Item 3 for a description of the Private Placement and Debt Exchange.

    On November 6, 2018, in connection with the entry into the Credit Agreement, pursuant to which, among other things, Squadron Medical provided a $35.0 million secured term loan to the Issuer, and pursuant to the terms of the Credit Agreement, the


    CUSIP No. 02081G201    13D    Page 8 of 15 Pages

     

    Issuer issued to each of Squadron Medical and Tawani, warrants to purchase 422,500 shares of Common Stock, for an aggregate of 845,000 shares of Common Stock, at a price of $3.15 per share (the “November 2018 Warrants”). Pursuant to the terms of the November 2018 Warrants, they are immediately exercisable, but cannot be exercised if, after giving effect to the issuance of Common Stock pursuant to the November 2018 Warrants, the holder of such warrant, together with any other persons acting as a group with the holder and any affiliates of the holder, would beneficially own in excess of 4.99% of the Issuer’s Common Stock outstanding immediately after giving effect to such issuance. The foregoing description of the November 2018 Warrants does not purport to be complete and is qualified in its entirety by reference to the form of November 2018 Warrants, which is filed herewith as Exhibit 4 and incorporated herein by reference.

    In connection with issuing the November 2018 Warrants, the Issuer entered into a registration rights agreement, dated November 6, 2018 (the “November 2018 Registration Rights Agreement”) with Squadron Medical and Tawani, whereby the Issuer agreed to register the resale of the Common Stock issuable pursuant to the November 2018 Warrants under the Securities Act. The foregoing description of the November 2018 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the November 2018 Registration Rights Agreement, which is filed herewith as Exhibit 5 and incorporated herein by reference.

    The Credit Agreement also provides Squadron Medical the right, during such period of time that the Issuer has unpaid or unsatisfied obligations under the Credit Agreement, to designate one or more individuals to attend, in a non-voting, observer capacity, all meetings of the Issuer’s board of directors, subject to certain limitations. Mr. Pelizzon was previously designated in such capacity, and is currently a member of the Issuer’s board of directors.

    On June 21, 2019, pursuant to an amendment to the Credit Agreement entered into in March 2019, pursuant to which, among other things, Squadron Medical provided an additional $30 million in draws to the Issuer, and in connection with the first draw following such amendment, the Issuer issued to each of Squadron Medical and Tawani warrants to purchase 2,419,355 shares of Common Stock, for an aggregate of 4,838,710 shares of Common Stock, at a price of $2.17 per share (the “June 2019 Warrants”). Pursuant to the terms of the June 2019 Warrants, they are immediately exercisable, but cannot be exercised if, after giving effect to the issuance of Common Stock pursuant to the June 2019 Warrants, the holder of such warrant, together with any other persons acting as a group with the holder and any affiliates of the holder, would beneficially own in excess of 4.99% of the Issuer’s Common Stock outstanding immediately after giving effect to such issuance. The foregoing description of the June 2019 Warrants does not purport to be complete and is qualified in its entirety by reference to the form of June 2019 Warrants, which is filed herewith as Exhibit 6 and incorporated herein by reference.

    In connection with issuing the June 2019 Warrants, the Issuer entered into a registration rights agreement, dated June 21, 2019 (the “June 2019 Registration Rights Agreement”) with Squadron Medical and Tawani, whereby the Issuer agreed to register the resale of the Common Stock issuable pursuant to the June 2019 Warrants under the


    CUSIP No. 02081G201    13D    Page 9 of 15 Pages

     

    Securities Act. The foregoing description of the June 2019 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the June 2019 Registration Rights Agreement, which is filed herewith as Exhibit 7 and incorporated herein by reference.

    On May 29, 2020, in connection with an amendment to the Credit Agreement, pursuant to which, among other things, Squadron Medical provided an additional $35.0 million secured term loan to the Issuer, and pursuant to the terms of the amendment, the Issuer issued to each of Squadron Medical and Tawani warrants to purchase 537,910 shares of Common Stock, for an aggregate of 1,075,820 shares of Common Stock, at a price of $4.88 per share (the “May 2020 Warrants”). Pursuant to the terms of the May 2020 Warrants, which expire May 29, 2027, they are immediately exercisable, but cannot be exercised if, after giving effect to the issuance of Common Stock pursuant to the May 2020 Warrants, the holder of such warrant, together with any other persons acting as a group with the holder and any affiliates of the holder, would beneficially own in excess of 4.99% of the Issuer’s Common Stock outstanding immediately after giving effect to such issuance. The foregoing description of the May 2020 Warrants does not purport to be complete and is qualified in its entirety by reference to the form of May 2020 Warrants, which is filed herewith as Exhibit 8 and incorporated herein by reference.

    In connection with issuing the May 2020 Warrants, the Issuer entered into a registration rights agreement, dated May 29, 2020 (the “May 2020 Registration Rights Agreement”) with Squadron Medical and Tawani, whereby the Issuer agreed to register the resale of the Common Stock issuable pursuant to the May 2020 Warrants under the Securities Act. The foregoing description of the May 2020 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the May 2020 Registration Rights Agreement, which is filed herewith as Exhibit 9 and incorporated herein by reference.

    Also in connection with the May 29, 2020 amendment to the Credit Agreement, the Issuer amended the November 2018 Warrants and the June 2019 Warrants to revise their expiration dates to May 29, 2027. The foregoing description of the amendments to the November 2018 Warrants and the June 2019 Warrants do not purport to be complete and are qualified in their entirety by reference to the amendments, which are filed herewith as Exhibit 10 and Exhibit 11 and incorporated herein by reference.

    The Reporting Persons intend to review their investment in the Issuer on a continuing basis. As a result of the Reporting Persons’ continuous review and evaluation of the business of the Issuer, the Reporting Persons may communicate with representatives of the Issuer, other shareholders and other persons regarding the Issuer. The Reporting Persons may, at any time and from time to time, purchase additional shares of Common Stock or dispose of shares of Common Stock held by them.

    Except as described in this Item 4, the Reporting Persons currently have no plans or proposals that relate to or would result in any transaction, event or action set forth in subsections (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to formulate plans or make proposals, and take such action with respect thereto, including any or all of the items set forth in subsections (a) through (j) of Item 4 of Schedule 13D and any other actions, as they may determine.


    CUSIP No. 02081G201    13D    Page 10 of 15 Pages

     

    Item 5. Interest in Securities of the Issuer

    (a) – (b) The table below sets forth, as of the date hereof, the beneficial ownership of shares of Common Stock for each of the Reporting Persons, based on 95,149,633 shares of Common Stock outstanding as of March 1, 2021, as reported in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

     

    Reporting Person   

    Amount

    beneficially

    owned

        

    Percent

    of class:

        Sole
    power
    to vote or
    to direct
    the vote:
         Shared
    power to
    vote or to
    direct the
    vote:
        

    Sole
    power to
    dispose or
    to direct
    the
    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Squadron Capital LLC

         11,395,045        12.0 %      —          11,395,045        —          11,395,045  

    Squadron Capital Holdings LLC

         11,395,045        12.0 %      —          11,395,045        —          11,395,045  

    Jennifer N. Pritzker

         14,160,050        14.9 %      32,200        14,127,850        32,200        14,127,850  

    David R. Pelizzon

         11,543,882        12.1 %      148,837        11,395,045        148,837        11,395,045  

    SC LLC is a manager-managed limited liability company and, as of the date hereof, directly holds 11,395,045 shares of Common Stock. The voting and investment decisions of SC LLC are made by its managing committee, consisting of Ms. Pritzker and Mr. Pelizzon. In such capacity each of Ms. Pritzker and Mr. Pelizzon may, for the purposes hereof, be deemed to beneficially own the shares of Common Stock held directly by SC LLC.

    Mr. Pelizzon directly holds 148,837 shares of Common Stock.

    Ms. Pritzker directly and/or jointly holds 30,200 shares of Common Stock, and may be deemed to have beneficial ownership of 2,000 shares of Common Stock held by Jennifer N. Pritzker Revocable Trust (“JNP Trust”) for which she serves as trustee. Ms. Pritzker may also, for the purposes hereof, be deemed to beneficially own (i) 2,722,805 shares of Common Stock held directly by Tawani, a manager-managed limited liability company whose controlling member is JNP Trust and where Ms. Pritzker is the one of two managers, and (ii) 10,000 shares of Common Stock held directly by Mary’s Go Round LLC, a manager-managed limited liability company whose manager and sole member is Tawani Enterprises, Inc., a corporation solely owned by JNP Trust and where Ms. Pritzker is the sole director.

    SCH LLC is a manager-managed limited liability company and the controlling member of SC LLC, and in such capacity may be deemed to beneficially own the shares of Common Stock held directly by SC LLC. The voting and investment decisions of SCH LLC are made by its managing committee, consisting of Mary Parthe, David Pelizzon and Michelle Nakfoor. The members of the managing committee of SCH LLC disclaim beneficial ownership as a result of serving as members of the managing committee.


    CUSIP No. 02081G201    13D    Page 11 of 15 Pages

     

    (c) Except as set forth in Item 4 and this Item 5, to the best knowledge of the Reporting Persons, neither Reporting Person nor any other person listed on Schedule A hereto has effected any transaction in the Ordinary Shares during the past 60 days.

    (d) To the best knowledge of the Reporting Persons, no other person has the right to receive dividends from, or the proceeds from the sale of, the Ordinary Shares listed in this Item 5.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    The information set forth under Items 3, 4, and 5 of this Schedule 13D is incorporated herein by reference. Except for the agreements described in this Schedule 13D, to the best knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise), among the Reporting Person or, to the best knowledge of the Reporting Person, any other person named in Schedule A hereto, or between such persons and any other person, with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

    Item 7. Material to Be Filed as Exhibits.

     

    Exhibit
    Number
      

    Exhibit Name

    1.    Joint Filing Agreement, dated as of March 11, 2021, pursuant to Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.
    2.    Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer on December 17, 2020)
    3.    Debt Exchange Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Issuer on December 17, 2020)
    4.    Form of November 2018 Warrants (incorporated by reference to Exhibit 4.11 to the Registration Statement on Form S-3/A filed by the Issuer on November 13, 2018)


    CUSIP No. 02081G201    13D    Page 12 of 15 Pages

     

    5.    November 2018 Registration Rights Agreement (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-3/A filed by the Issuer on November 13, 2018)
    6.    Form of June 2019 Warrants (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer on June 27, 2019)
    7.    June 2019 Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Issuer on June 27, 2019)
    8.    Form of May 2019 Warrants (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Issuer on June 4, 2020)
    9.    May 2020 Registration Rights Agreement (incorporated by reference to Exhibit 4.4 to the Current Report on Form 8-K filed by the Issuer on June 4, 2020)
    10.    Amendment to November 2018 Warrants (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed by the Issuer on June 4, 2020)
    11.    Amendment to June 2019 Warrants (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed by the Issuer on June 4, 2020)


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: March 11, 2021

     

    Squadron Capital LLC
    By:  

    /s/ David R. Pelizzon

      Name:   David R. Pelizzon
      Title:   President
    Squadron Capital Holdings LLC
    By:  

    /s/ Mary Parthe

      Name:   Mary Parthe
      Title:   Manager

    /s/ Jennifer N. Pritzker

    Jennifer N. Pritzker

    /s/ David R. Pelizzon

    David R. Pelizzon

    [Signature Page to Schedule 13D]


    CUSIP No. 02081G201    13D    Page 14 of 15 Pages

     

    Schedule A

    Squadron Capital LLC

    The name, business address, title, present principal occupation or employment and citizenship of each member of the managing committee and each executive officer of SC LLC is set forth below. If no business address is given, the managing committee member’s or executive officer’s business address is 18 Hartford Rd., Granby, CT 06035. Unless otherwise indicated, each occupation set forth opposite an individual’s name refers to SC LLC.

    Managing Committee

     

    Name

      

    Present Principal Occupation or Employment and
    Name and Principal Address of Corporation for
    Which Employment is Conducted

      

    Citizenship

    Jennifer N. Pritzker   

    President and Chief Executive Officer of Tawani Enterprises, Founder and Chair of the Pritzker Military Museum and Library, Founder of the Pritzker Military Foundation, and Founder of the Tawani Foundation

    104 S. Michigan Ave., Chicago, IL 60603

       U.S.A.
    David R. Pelizzon    President    U.S.A.

    Executive Officers

     

    Name

      

    Present Principal Occupation or Employment and
    Name and Principal Address of Corporation for
    Which Employment is Conducted

      

    Citizenship

    David R. Pelizzon    President    U.S.A.
    Douglas Pascoe    Chief Financial Officer    U.S.A.
    Harold Ruf    Chief Operating Officer    U.S.A.


    CUSIP No. 02081G201    13D    Page 15 of 15 Pages

     

    Squadron Capital Holdings LLC

    The name, business address, title, present principal occupation or employment and citizenship of each member of the managing committee of SCH LLC is set forth below. If no business address is given, the managing committee member’s business address is 104 S. Michigan Ave., Chicago, IL 60603.

    Managing Committee

     

    Name

      

    Present Principal Occupation or Employment and
    Name and Principal Address of Corporation for
    Which Employment is Conducted

      

    Citizenship

    Mary Parthe    Chief Investment Officer of Tawani Enterprises, Inc.    U.S.A.
    David R. Pelizzon   

    President of Squadron Capital LLC

    18 Hartford Rd., Granby, CT 06035

       U.S.A.
    Michelle Nakfoor    General Counsel of Tawani Enterprises, Inc.    U.S.A.
    Get the next $ATEC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATEC

    DatePrice TargetRatingAnalyst
    6/16/2025$18.00Buy
    Lake Street
    8/1/2024Overweight → Equal-Weight
    Morgan Stanley
    7/8/2024$19.00Overweight
    Barclays
    2/9/2024$26.00Overweight
    Wells Fargo
    12/19/2023$16.00 → $18.00Buy
    Needham
    10/20/2023$22.00Buy
    ROTH MKM
    10/12/2022$12.00Buy
    Jefferies
    9/12/2022$13.00Overweight
    Morgan Stanley
    More analyst ratings

    $ATEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

      Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri

      4/4/24 9:05:00 AM ET
      $ATEC
      $SYK
      Medical/Dental Instruments
      Health Care
    • John Booth to Retire as CEO of Spineology Inc.

      Brian Snider Appointed New CEO Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director. Snider joins Spineology with nearly twenty years of progressive leadership experience in the

      11/9/23 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Financials

    Live finance-specific insights

    See more
    • ATEC to Report First Quarter 2025 Financial Results on May 1, 2025

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2025 financial results on May 1, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducemen

      4/14/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Third Quarter Financial Results on October 30, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu

      10/7/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC to Report Second Quarter Financial Results on July 31, 2024

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2024 financial results on July 31, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.

      7/10/24 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    SEC Filings

    See more
    • SEC Form S-8 filed by Alphatec Holdings Inc.

      S-8 - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:46:41 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alphatec Holdings, Inc. (0001350653) (Filer)

      6/13/25 4:03:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Alphatec Holdings Inc.

      144 - Alphatec Holdings, Inc. (0001350653) (Subject)

      6/11/25 11:15:31 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street resumed coverage on Alphatec with a new price target

      Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00

      6/16/25 8:53:19 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Alphatec downgraded by Morgan Stanley

      Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight

      8/1/24 3:06:35 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Barclays initiated coverage on Alphatec with a new price target

      Barclays initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00

      7/8/24 7:34:11 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bakst Evan bought $201,600 worth of shares (35,000 units at $5.76) (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:32:07 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Pelizzon David R bought $149,998 worth of shares (25,796 units at $5.81), increasing direct ownership by 8% to 331,696 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/26/24 4:27:25 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Demski David M bought $283,500 worth of shares (50,000 units at $5.67), increasing direct ownership by 21% to 288,441 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      8/21/24 10:00:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • ATEC Reports First Quarter 2025 Financial Results and Raises Full-Year Guidance

      Surgical revenue grew 24%; total revenue grew 22% Full-year revenue and profitability guidance increased Successfully refinanced convertible debt to 2030 maturity Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2025, and recent corporate highlights. First Quarter 2025 Financial Results   Quarter Ended March 31, 2025 Total revenue $169 million GAAP gross margin 69% Non-GAAP gross margin 70% GAAP operating expenses $160 million Non-GAAP operating expenses $124 million GAAP net income /

      5/1/25 4:05:00 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • ATEC Launches PTP™ Corpectomy, The Next Evolution of Lateral Approach Surgery

      Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced the commercial launch of its Prone TransPsoas (PTP™) Corpectomy system. This milestone marks the continued evolution of ATEC's PTP surgical approach, expanding its capabilities to include deformity and corpectomy procedures for complex pathologies of the thoracolumbar spine. "PTP Corpectomy represents a significant step forward in ATEC's commitment to improving patient outcomes in the most complex spine surgeries," said Pat Miles, Chairman and Chief Executive Officer. "By integrating advanced surgical techniques within a fully proceduralized

      4/21/25 9:00:00 AM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Lish Scott sold $251,588 worth of shares (22,727 units at $11.07), decreasing direct ownership by 3% to 748,918 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/17/25 6:00:06 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Woods Ward W Jr was granted 15,131 shares, increasing direct ownership by 11% to 154,291 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:17 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • Director Valentine Keith was granted 15,131 shares, increasing direct ownership by 18% to 97,271 units (SEC Form 4)

      4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

      6/13/25 5:30:16 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care

    $ATEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Alphatec Holdings Inc.

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      11/12/24 8:04:57 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      3/22/24 7:57:56 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

      SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

      5/12/23 4:51:18 PM ET
      $ATEC
      Medical/Dental Instruments
      Health Care